Table 3 Current clinical investigations of nanomaterials used for cancer diagnostics and imaging
From: Cancer nanotechnology: current status and perspectives
NCT Number | Title | Conditions | Interventions | Phases |
|---|---|---|---|---|
NCT04825002 | Detection of clinically significant prostate cancer using a urinary multimarker sensor | Prostate cancer | Diagnostic Test: Urinary multimarker sensor | Not Applicable |
NCT04696744 | Prospective Study for the prognostic and predictive role of circulating tumor cells in patients with oropharyngeal advanced squamous cell carcinoma: CTCO (circulating tumor cells in the oropharynx) | Circulating tumor cell/oropharyngeal cancer | Biological: CTC detection | |
NCT04661176 | Evaluation of the Sentinelâ„¢ PCC4 assay for diagnosis, prognosis and monitoring of prostate cancer in puerto rico | Prostate cancer | Diagnostic Test: miR Sentinelâ„¢ PCC4 Assay | |
NCT04482803 | Targeted biopsy of carbon NPs labelled axillary node for cN + breast cancer | Location and Biopsy of Axillary Lymph Nodes | Drug: Carbon NPs suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes | Not Applicable |
NCT04300673 | Radio guided lymph node dissection in oligometastatic prostate cancer patients | Prostate cancer/lymph node metastases | Procedure: Radio guided surgery (RGS) using Indium-labelled PSMA | Phase 1/2 |
NCT04290923 | Determination of blood tumor cells | Leukemia, lymphocytic, chronic, b-cell/abnormalities cell epithelial | ||
NCT04261777 | Ferumoxtran-10-enhanced MRI in prostate cancer patients | Prostate cancer/metastasis/prostatectomy | Drug: Ferrotran® (Ferumoxtran-10) | Phase 3 |
NCT04239105 | Detection of circulating tumor cells in breast cancer patients using a novel microfluidic and Raman spectrum device | Breast neoplasms/circulating tumor cells | Device: Microfluidic and Raman spectrum | |
NCT04167969 | The use of NPs to guide the surgical treatment of prostate cancer | Prostate cancer | Drug: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots/Diagnostic Test: PET/MRI/Other: Blood and urine sampling/Procedure: laparoscopic radical prostatectomy and bilateral pelvic LN dissection | Phase 1 |
NCT04167722 | How does prostate cancer metastasize? Studying the role of secreted packages (exosomes) from fat tissue in lean and obese patients | Prostate cancer/obesity | Procedure: Robotic radical prostatectomy | |
NCT03967652 | Cancer diagnoses from exhaled breath with Na-nose | Volatile organic compounds/cancer/diagnoses disease | Diagnostic Test: Nanomaterial-based sensors | |
NCT03817307 | Validation of USPIO-enhanced MRI for detection of lymph node metastases in head and neck carcinoma | Head and neck squamous cell carcinoma | Diagnostic Test: USPIO-enhanced MRI | Not Applicable |
NCT03694483 | Prostasomes as diagnostic tool for prostate cancer detection | Prostate cancer | Diagnostic Test: Genetic analysis for the detection of prostasomes | |
NCT03550001 | Carbon NPs as lymph node tracer in rectal cancer after neoadjuvant radiochemotherapy | Rectal cancer | Procedure: Injection CNP before NAT | Not Applicable |
NCT03427450 | Harvest of CTCs from mbc patients using the Parsortixâ„¢ PC1 system | Healthy volunteers/breast cancer, metastatic | Diagnostic Test: Blood draw | |
NCT03280277 | Ferumoxytol-enhanced MRI in imaging lymph nodes in patients with locally advanced rectal cancer | Locally advanced rectal carcinoma/Stage III rectal cancer AJCC v7/Stage IIIA rectal cancer AJCC v7/Stage IIIB rectal cancer AJCC v7/Stage IIIC rectal cancer AJCC v7 | Procedure: Contrast-enhanced magnetic resonance imaging/Drug: Ferumoxytol | Early Phase 1 |
NCT03134846 | Image guided surgery for margin assessment of head and neck cancer Using Cetuximab-IRDye800CW conjugate | Head and neck squamous cell carcinoma/margin assessment | Drug: Cetuximab-IRDye800CW | Phase 1/2 |
NCT02857218 | Ferumoxytol-Enhanced MRI in imaging lymph nodes in patients With Stage IIB-IIIC esophageal cancer | Stage IIB esophageal cancer AJCC v7/Stage III esophageal cancer AJCC v7/Stage IIIA esophageal cancer AJCC v7/Stage IIIB esophageal cancer AJCC v7/Stage IIIC esophageal cancer AJCC v7 | Drug: Ferumoxytol/Procedure: Magnetic resonance imaging | Early Phase 1 |
NCT02751606 | Nano MRI on 7 Tesla in rectal and breast cancer | Rectal neoplasms/breast neoplasms | Drug: ferumoxtran-10/Device: 7 Tesla MRI/Device: 3 Tesla MRI | Phase 3 |
NCT02106598 | Targeted silica NPs for real-time image-guided intraoperative mapping of nodal metastases | Head and neck melanoma | Drug: fluorescent cRGDY-PEG-Cy5.5-C dots | Phase 1/2 |
NCT01411904 | A novel magnetic needle using iron oxide NPs for the detection of leukemia | Leukemia | Device: MagProbe (TM) | Not Applicable |
NCT01359436 | e- Ab sensor-based real-time detection of mutant EGFR in clinical specimens from patients of NSCLC | NSCLC (NSCLC) | Device: Electrosensing antibody probing system (e- Ab sensing) | Not Applicable |